Defendants in Tuschl-I IP Suit Cast Doubt on Claims of Pending Patent Issuance | GenomeWeb

By Doug Macron

Although Alnylam Pharmaceuticals and the Max Planck Institute contend in a lawsuit that the US Patent and Trademark Office is poised to issue a patent from the Tuschl-I intellectual property portfolio, the defendants in the case argued this week that this expectation is mere speculation.

For this and other reasons, the defendants told the court, Alnylam and Max Planck's request for a court order essentially blocking any kind of Tuschl-I patent issuance is unnecessary and potentially damaging.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.